Armistice Capital, LLC Travere Therapeutics, Inc. Call Options Transaction History
Armistice Capital, LLC
- $7.34 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TVTX
# of Institutions
184Shares Held
89.5MCall Options Held
66.9KPut Options Held
265K-
Black Rock Inc. New York, NY7.8MShares$64.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.37MShares$60.6 Million1.88% of portfolio
-
State Street Corp Boston, MA6.61MShares$54.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.27MShares$51.5 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.61MShares$37.9 Million0.04% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $528M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...